Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Articles

Page Path
HOME > Cancer Res Treat > Volume 35(4); 2003 > Article
Original Article
Alterations in Promoter Usage and Expression Levels of Insulin-like Growth Factor-II and H19 Genes in Cervical and Endometrial Cancer
Chan Lee, Seung Jo Kim, Joong Yol Na, Chang Suk Park, Sun Young Lee, In Ho Kim, Yu Kyoung Oh
Cancer Research and Treatment 2003;35(4): 314-322.
DOI: https://doi.org/10.4143/crt.2003.35.4.314
Published online: August 31, 2003
1Comprehensive Gynecologic Cancer Center, Bundang CHA MedicalCenter, Seongnam, Gyeonggi-do, Korea. chanoncology@msn.com
2Department of Obstetrics and Gynecology, College ofMedicine, Korea University, Seoul, Korea.
3Department of Microbiology and Institute of MedicalResearch, College of Medicine, Pochon CHA University,Pocheon, Korea.
  • 4,531 Views
  • 35 Download
  • 8 Crossref
  • 0 Scopus
prev next

PURPOSE
The biallelic expression of insulin-like growth factor-II (IGF2) and H19 has been reported to be associated with the progression of several tumors. Here, the promoter usage and expression levels of IGF2 and H19 are reported to be altered in cervical and endometrial cancers showing loss of imprinting (LOI).
MATERIALS AND METHODS
The imprinting status of IGF2 and H19 was examined in 32 cervical carcinomas, their matched normal tissues, 13 endometrial cancer and 33 normal endometrial tissues.
RESULTS
The LOI of IGF2 was observed in 7 of 18 (39%) and 1 of 13 (8.3%) informative cervical carcinomas and informative endometrial cancers, respectively. The LOI of the H19 gene was detected in 5 of 14 (36%) and in all 11 (100%) informative cervical carcinoma cases and informative endometrial cancer cases, respectively. The use of promoter P1 was observed in the LOI tumors of IGF2, but not in the tumors showing maintenance of IGF2 imprinting (MOI), or in cervical and endometrial cancers. Unlike MOI tumors, some LOI tumors revealed a lack of IGF2 transcription from the promoter P3. The LOI tumors of IGF2 showed increased expression of the IGF2 level, but a down-regulation of the H19, relative to normal tissues, whereas the MOI tumors revealed no significant alterations.
CONCLUSION
These results suggest that the promoter P1 could be involved in the biallelic expression of IGF2, and that the altered expression of the IGF2 and H19 levels might be associated with the progression of cervical and endometrial cancers that exhibit biallelic IGF2 expression.

  • Cite
    CITE
    export Copy Download
    Close
    Download Citation
    Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

    Format:
    • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
    • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
    Include:
    • Citation for the content below
    Alterations in Promoter Usage and Expression Levels of Insulin-like Growth Factor-II and H19 Genes in Cervical and Endometrial Cancer
    Cancer Res Treat. 2003;35(4):314-322.   Published online August 31, 2003
    Close

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP